🇺🇸 Colloidal bismuth pectin in United States

51 US adverse-event reports

Marketing authorisation

FDA

  • Status: approved

Safety signals — FAERS

Adverse reaction reports describe suspected side effects. A report does not mean the drug caused the event — co-medications, underlying disease and coincidence all contribute.

Most-reported reactions

  1. Drug Interaction — 10 reports (19.61%)
  2. Hypoglycaemia — 10 reports (19.61%)
  3. Drug Eruption — 7 reports (13.73%)
  4. Chest Discomfort — 4 reports (7.84%)
  5. Cold Sweat — 4 reports (7.84%)
  6. Muscle Spasms — 4 reports (7.84%)
  7. Pruritus — 4 reports (7.84%)
  8. Melaena — 3 reports (5.88%)
  9. Urticaria — 3 reports (5.88%)
  10. Anaphylactic Shock — 2 reports (3.92%)

Source database →

Colloidal bismuth pectin in other countries

Same drug, different regulators. Each page below lists the local marketing authorisation, HTA position, pricing, and adverse-event data.

Frequently asked questions

Is Colloidal bismuth pectin approved in United States?

Yes. FDA has authorised it.

Who is the marketing authorisation holder for Colloidal bismuth pectin in United States?

Second Affiliated Hospital, School of Medicine, Zhejiang University is the originator. The local marketing authorisation holder may differ — check the official source linked above.